KR20250021331A - mazdutide를 사용하는 치료 방법 - Google Patents

mazdutide를 사용하는 치료 방법 Download PDF

Info

Publication number
KR20250021331A
KR20250021331A KR1020247042558A KR20247042558A KR20250021331A KR 20250021331 A KR20250021331 A KR 20250021331A KR 1020247042558 A KR1020247042558 A KR 1020247042558A KR 20247042558 A KR20247042558 A KR 20247042558A KR 20250021331 A KR20250021331 A KR 20250021331A
Authority
KR
South Korea
Prior art keywords
weeks
target compound
patient
week
continuously
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247042558A
Other languages
English (en)
Korean (ko)
Inventor
청항 차이
멍 리우
후안 덩
바일리 송
지에 원
Original Assignee
이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 filed Critical 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드
Publication of KR20250021331A publication Critical patent/KR20250021331A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Dermatology (AREA)
KR1020247042558A 2022-06-01 2023-05-10 mazdutide를 사용하는 치료 방법 Pending KR20250021331A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210622648.7 2022-06-01
CN202210622648 2022-06-01
PCT/CN2023/093311 WO2023231730A2 (zh) 2022-06-01 2023-05-10 使用mazdutide的治疗方法

Publications (1)

Publication Number Publication Date
KR20250021331A true KR20250021331A (ko) 2025-02-12

Family

ID=89026916

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247042558A Pending KR20250021331A (ko) 2022-06-01 2023-05-10 mazdutide를 사용하는 치료 방법

Country Status (8)

Country Link
US (1) US20250296973A1 (cg-RX-API-DMAC7.html)
EP (1) EP4534095A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025518227A (cg-RX-API-DMAC7.html)
KR (1) KR20250021331A (cg-RX-API-DMAC7.html)
CN (1) CN119584980A (cg-RX-API-DMAC7.html)
AU (1) AU2023281591A1 (cg-RX-API-DMAC7.html)
CA (1) CA3257926A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023231730A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202617173A (zh) * 2021-06-25 2026-05-01 大陸商信達生物製藥(蘇州)有限公司 Mazdutide的應用
EP4788362A1 (en) * 2023-10-03 2026-08-12 Innovent Biologics (Suzhou) Co., Ltd. Methods of treating diabetes and obesity
WO2026002224A1 (en) * 2024-06-27 2026-01-02 Innovent Biologics (Suzhou) Co., Ltd. Method of treating polycystic ovary syndrome

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI783244B (zh) * 2015-06-22 2022-11-11 美商美國禮來大藥廠 升糖素及glp-1共激動劑化合物
US11419918B2 (en) * 2017-11-06 2022-08-23 Shenzhen Turier Biotech Co., Ltd. Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide
CN111423506B (zh) * 2019-11-08 2023-06-27 成都奥达生物科技有限公司 一种glp-1化合物
TW202617173A (zh) * 2021-06-25 2026-05-01 大陸商信達生物製藥(蘇州)有限公司 Mazdutide的應用

Also Published As

Publication number Publication date
US20250296973A1 (en) 2025-09-25
AU2023281591A1 (en) 2025-01-02
CA3257926A1 (en) 2025-04-09
EP4534095A2 (en) 2025-04-09
EP4534095A4 (en) 2026-05-27
CN119584980A (zh) 2025-03-07
WO2023231730A3 (zh) 2024-01-25
WO2023231730A2 (zh) 2023-12-07
JP2025518227A (ja) 2025-06-12

Similar Documents

Publication Publication Date Title
US20250296973A1 (en) Treatment method using mazdutide
US11026999B2 (en) Insulin glargine/lixisenatide fixed ratio formulation
US20240293513A1 (en) Use of mazdutide
KR20080110852A (ko) 대사질환 치료용 엔도테린 및 엔도테린 수용체 작용제
JPH01233227A (ja) 高インシュリン症の二次効果治療及び予防用医薬組成物
JP2024038042A (ja) 肥満の治療および体重管理のためのglp-1組成物
WO2024042518A1 (en) Glp-1 receptor antagonist and methods of use thereof
AU2025205229B2 (en) Compositions and methods for treating diabetes
TW202500575A (zh) 具有或不具有體重相關合併症之過重或肥胖成人之治療
HK40118093A (en) Treatment method using mazdutide
KR20110052990A (ko) 인슐린 글라르긴 및 메트포르민에 대한 부가적 요법을 포함하는 2형 당뇨병의 치료 방법
KR20250095833A (ko) 에페글레나타이드를 유효성분으로 포함하는 약학 조성물 및 이의 투여 요법
HK40110048A (en) Use of mazdutide
WO2026046202A1 (zh) Glp-1/gip肽或含有其的药物组合物的用途
WO2026037397A1 (zh) Glp-1类似物的医药用途
TW202529797A (zh) Glp-1類似物治療代謝疾病的方法及醫藥用途
TW202140061A (zh) 用於治療2型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及glp-1協同促效劑
TW202506170A (zh) 糖尿病之治療
KR20260022330A (ko) 대사 장애의 치료에 사용하기 위한 glp-1 유사체
TW202532097A (zh) 治療糖尿病及肥胖的方法
AU2009238272A1 (en) Method of treatment of diabetes type 2 comprising add-on therapy to metformin

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000